Michael Cherny, an analyst from Leerink Partners, maintained the Buy rating on Align Tech (ALGN – Research Report). The associated price target remains the same with $280.00.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Michael Cherny has given his Buy rating due to a combination of factors that consider both potential challenges and growth opportunities for Align Tech. Despite the potential impact of tariffs on aligners manufactured in Mexico for the Americas market, Cherny believes that the company has strategies in place to mitigate these effects. These strategies include potential price adjustments, shifting production to other facilities, and exploring cost-cutting measures.
Moreover, Cherny points out that Align Tech has several growth drivers beyond its mitigation efforts, which could help counterbalance the tariff pressures. He expects the company’s management to address these impacts comprehensively in upcoming discussions. Cherny’s analysis includes a sensitivity study projecting a 7-8% potential EPS impact without any offsets, emphasizing that this is a gross impact estimate. Overall, his Buy rating reflects confidence in Align Tech’s ability to navigate these challenges effectively while capitalizing on growth opportunities.
According to TipRanks, Cherny is a 4-star analyst with an average return of 3.6% and a 53.13% success rate. Cherny covers the Healthcare sector, focusing on stocks such as Walgreens Boots Alliance, GoodRx Holdings, and CVS Health.
In another report released on January 27, Mizuho Securities also maintained a Buy rating on the stock with a $295.00 price target.